| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Published online before print November 17, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,1
* Division of Nephrology, Department of Pediatrics, and
Division of Hematology, Department of Medicine, University of Washington, Seattle
1 Correspondence: Division of Hematology, Harborview Medical Center, Mailstop 359756, 325 Ninth Avenue, Seattle, WA 98115. E-mail: jharlan{at}u.washington.edu
As our understanding of integrins as multifunctional adhesion and signaling molecules has grown, so has their recognition as potential therapeutic targets in human diseases. Leukocyte integrins are of particular interest in this regard, as they are key molecules in immune-mediated and inflammatory processes and are thus critically involved in diverse clinical disorders, ranging from asthma to atherosclerosis. Antagonists that interfere with integrin-dependent leukocyte trafficking and/or post-trafficking events have shown efficacy in multiple preclinical models, but these have not always predicted success in subsequent clinical trials (e.g., ischemia-reperfusion disorders and transplantation). However, recent successes of integrin antagonists in psoriasis, inflammatory bowel disease, and multiple sclerosis demonstrate the tremendous potential of antiadhesion therapy directed at leukocyte integrins. This article will review the role of the leukocyte integrins in the inflammatory process, approaches to targeting leukocyte integrins and their ligands, and the results of completed clinical trials.
Key Words: adhesion • clinical • trials • inflammation
This article has been cited by other articles:
|
|
 |
|
  Y. Miyazaki, M. Bunting, D. M. Stafforini, E. S. Harris, T. M. McIntyre, S. M. Prescott, V. S. Frutuoso, F. C. Amendoeira, D. de Oliveira Nascimento, A. Vieira-de-Abreu, et al. Integrin {alpha}D 2 Is Dynamically Expressed by Inflamed Macrophages and Alters the Natural History of Lethal Systemic Infections J. Immunol., January 1, 2008; 180(1): 590 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zarbock and K. Ley Mechanisms and Consequences of Neutrophil Interaction with the Endothelium Am. J. Pathol., January 1, 2008; 172(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kong, M. Scully, C. S. Shelley, and S. P. Colgan Identification of Pur{alpha} as a New Hypoxia Response Factor Responsible for Coordinated Induction of the beta2 Integrin Family J. Immunol., August 1, 2007; 179(3): 1934 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Priestley, L. M. Scott, T. Ulyanova, and T. Papayannopoulou Lack of {alpha}4 integrin expression in stem cells restricts competitive function and self-renewal activity Blood, April 1, 2006; 107(7): 2959 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Iyer, R. S. Agrawal, C. R. Thompson, S. Thompson, J. A. Barton, and D. J. Kusner Phospholipase D1 Regulates Phagocyte Adhesion J. Immunol., March 15, 2006; 176(6): 3686 - 3696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-S. J. Sung, S. M. Fu, C. E. Rose Jr., F. Gaskin, S.-T. Ju, and S. R. Beaty A Major Lung CD103 ({alpha}E)-beta7 Integrin-Positive Epithelial Dendritic Cell Population Expressing Langerin and Tight Junction Proteins J. Immunol., February 15, 2006; 176(4): 2161 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Reichel, A. Khandoga, H.-J. Anders, D. Schlondorff, B. Luckow, and F. Krombach Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue J. Leukoc. Biol., January 1, 2006; 79(1): 114 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Mizgerd Mac-1 mediates migration to lymph nodes Blood, November 1, 2005; 106(9): 2927 - 2928. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Stokes and D. N. Granger Gaining More From Gamma Globulins Circulation, September 27, 2005; 112(13): 1918 - 1920. [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Morrell, K. Matsushita, and C. J. Lowenstein A Novel Inhibitor of N-Ethylmaleimide-Sensitive Factor Decreases Leukocyte Trafficking and Peritonitis J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
